Date:11/13/2009

23,957,988 18,802,872 TOTAL LIABILITIES AND EQUITY $37,245,968 $28,641,878 Kun Run Biotechnology, Inc. and Subsidiaries Consolidated Statements of Operations (Unaudited) (In United States dollars) Three months ended Nine months ended September 30, September 30, (Unaudited) (Unaudited) 2009 2008 2009 2008 Sales revenue $4,048,877 $2,449,618 $10,139,543 $7,799,687 Cost of sales 1,211,070 693,242 2,976,593 2,247,912 Gross profit 2,837,807 1,756,376 7,162,950 5,551,775 Operating expenses Administrative expenses 285,889 257,968 678,314 742,823 Research and developments costs 90,335 107,896 189,647 234,136 Selling expenses 69,882 271,460 287,425 555,540 446,106 637,324 1,155,386 1,532,499 Income from operations 2,391,701 1,119,052 6,007,564 4,019,276 Interest income 49,466 374 116,426 1,516 Other income 116,682 63,312 315,926 165,908 Government subsidy income 32,768 104 40,093 9,729 Finance costs (170,622) (140,690) (428,440) (415,311) Income before income taxes and noncontrolling interest 2,419,995 1,042,152 6,051,569 3,781,118 Income taxes (353,654) (168,803) (902,662) (300,383) Net income before noncontrolling interest 2,066,341 873,349 5,148,907 3,480,735 Net income attributable to noncontrolling interest
'/>"/>

SOURCE Kun Run Biotechnology, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
2. Misonix Announces New Distribution Agreement for Saudi Arabia and Other Middle Eastern Countries
3. Milestone Scientific Announces Third Quarter 2009 Results
4. EF Johnson Technologies Announces Third Quarter Results
5. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
6. LifeVantage Announces Unaudited First Quarter Fiscal 2010 Financial and Operating Results
7. Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome
8. WIFH Atlanta Announces Breakthrough Technique in Laser Hair Removal for Ethnic Skin Types
9. Mithridion Announces Progress With Drugs for Alzheimers Disease and Schizophrenia
10. Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results
11. Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering